Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib

PURPOSE: Preclinical studies show that activation of AMP kinase by phenformin can augment the cytotoxic effect and RAF inhibitors in BRAF V600-mutated melanoma. We conducted a phase Ib dose-escalation trial of phenformin with standard dose dabrafenib/trametinib in patients with metastatic BRAF V600-...

Descripción completa

Detalles Bibliográficos
Autores principales: Chapman, Paul B., Klang, Mark, Postow, Michael A., Shoushtari, Alexander Noor, Sullivan, Ryan J., Wolchok, Jedd D., Merghoub, Taha, Budhu, Sadna, Wong, Phillip, Callahan, Margaret K., Zheng, Bin, Zippin, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695100/
https://www.ncbi.nlm.nih.gov/pubmed/37930123
http://dx.doi.org/10.1158/2767-9764.CRC-23-0296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695100/
https://www.ncbi.nlm.nih.gov/pubmed/37930123
http://dx.doi.org/10.1158/2767-9764.CRC-23-0296

Ejemplares similares